Hemispherx BioPharma, Inc (NYSE:HEB) saw a large increase in short interest in the month of August. As of August 15th, there was short interest totalling 964,695 shares, an increase of 23.3% from the July 31st total of 782,505 shares. Currently, 3.5% of the company’s shares are sold short. Based on an average daily volume of 203,044 shares, the days-to-cover ratio is presently 4.8 days.
An institutional investor recently raised its position in Hemispherx BioPharma stock. Vanguard Group Inc. boosted its position in shares of Hemispherx BioPharma, Inc (NYSE:HEB) by 0.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 453,805 shares of the specialty pharmaceutical company’s stock after buying an additional 2,709 shares during the period. Vanguard Group Inc. owned 1.56% of Hemispherx BioPharma worth $227,000 as of its most recent SEC filing.
Shares of Hemispherx BioPharma (NYSE HEB) traded up 1.5676% on Thursday, hitting $0.3758. The company’s stock had a trading volume of 66,315 shares. The company’s market cap is $10.96 million. The stock’s 50 day moving average is $0.44 and its 200-day moving average is $0.52. Hemispherx BioPharma has a 52 week low of $0.30 and a 52 week high of $2.40.
Hemispherx BioPharma (NYSE:HEB) last announced its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter. Hemispherx BioPharma had a negative return on equity of 79.55% and a negative net margin of 3,358.33%. The business had revenue of $0.21 million for the quarter. On average, equities research analysts anticipate that Hemispherx BioPharma will post $0.00 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Hemispherx BioPharma, Inc (HEB) Short Interest Update” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/2849496/hemispherx-biopharma-inc-heb-short-interest-update.html.
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.